We are delighted to announce that Kurt Herpel, CEO, and Dr. Paul Perco, Computational Biology Lead of Delta4, are looking […]
Author: Kurt Herpel
Case Study: Unravelling the Multifaceted Potential of Iguratimod with Delta4’s Hyper-C Platform
Diving deep into the realms of computational drug repurposing, Delta4 leveraged its state-of-the-art Hyper-C platform with an ambitious objective: to […]
Delta4 At BIO-Europe
Delta4 Will Attend BIO-Europe 2023 Delta4 is thrilled to announce that our CEO, Kurt Herpel, and CSO, Klaus Kratochwill, will […]
Delta4 at RExPO: Pushing the Boundaries of Drug Repurposing
We are thrilled to announce that Delta4 will be in attendance at this year’s RExPO23, a landmark event in the […]
Reactome Spotlights Delta4’s Computational Drug Repositioning of Clopidogrel for FSGS
We are honored to announce that our publication on the computational drug repositioning of clopidogrel has been highlighted in the […]
Delta4 joins the EU-funded COST action PerMediK (Personalized medicine in chronic kidney disease: improved outcome based on Big Data)
The scientific goal of PerMediK is to foster development toward personalized medicine in chronic kidney disease (CKD), based on multidimensional […]
Protected: AI Drug Discovery Services Companies Forging the Future of Medicine
There is no excerpt because this is a protected post.
Delta4’s Innovation Shines: OntoloViz Article Published in Bioinformatics Advances Journal
We are thrilled to announce that our journal article, titled “OntoloViz: a GUI for interactive visualization of ranked disease or […]
Drug Indication Expansion: Unlocking Untapped Potential
In the vast ecosystem of the pharmaceutical industry, drug indication expansion plays a pivotal role in maximizing the potential of […]
Advancing Healthcare Through Drug Discovery Services: Unleashing the Power of Innovation
In the realm of healthcare, the journey from a promising drug idea to an effective therapy is not a straightforward […]